Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses

被引:30
作者
Yan, Z [1 ]
Rafferty, B [1 ]
Caldwell, GW [1 ]
Masucci, JA [1 ]
机构
[1] Johnson & Johnson Pharmaceut Res & Dev LLP, Div Drug Discovery, Spring House, PA 19477 USA
关键词
CYPs; irreversible inhibition; mechanism-based inhibition;
D O I
10.1007/BF03192339
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this study we have evaluated the reliability of a fluorescence-based method used for rapid identification of irreversible CYP inhibitors (mechanism-based inhibitors). This was accomplished by comparing the time-dependence pattern of IC50 values from fluorometric kinetic measurements. For irreversible CYP inhibitors, IC50 values decreased as incubation proceeded. This was due to progressive inactivation of corresponding enzymes by reactive metabolites generated during the incubation. This change pattern was confirmed using a number of known irreversible CYP inhibitors, including furafylline, midazolam, erythromycin, clarithromycin, oleandomycin, 17alpha-ethynylestradiol and verapamil. The pattern was different in reversible inhibition, depending upon the compounds tested in the fluorometric kinetic assay. For some compounds, such as clotrimazole, IC50 values remained relatively stable, whereas other compounds, such as miconazole, terfenadine and ketoconazole showed a significant increase with incubation time. Monitoring tested compounds by LC-MS/MS during the incubation confirmed that increases of IC50 were probably caused by the loss of inhibitors, resulting from either metabolic degradation, or non-specific binding to microsomal proteins.
引用
收藏
页码:281 / 287
页数:7
相关论文
共 23 条
[1]  
Bachus R, 1999, PHARMACOGENETICS, V9, P661
[2]  
Bapiro TE, 2001, DRUG METAB DISPOS, V29, P30
[3]  
BENNETT M, 2000, DRUG METAB DISPOS, V28, P125
[4]  
Bourrie M, 1996, J PHARMACOL EXP THER, V277, P321
[5]  
Chu IH, 2000, RAPID COMMUN MASS SP, V14, P207, DOI 10.1002/(SICI)1097-0231(20000229)14:4<207::AID-RCM863>3.0.CO
[6]  
2-#
[7]   Fluorometric screening for metabolism-based drug-drug interactions [J].
Crespi, CL ;
Stresser, DM .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2000, 44 (01) :325-331
[8]   Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450 [J].
Crespi, CL ;
Miller, VP ;
Penman, BW .
ANALYTICAL BIOCHEMISTRY, 1997, 248 (01) :188-190
[9]  
Gibbs MA, 1999, DRUG METAB DISPOS, V27, P180
[10]  
Griffin JP, 1998, ADVERSE DRUG REACT T, V17, P59